These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38909137)

  • 1. Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms.
    Elvebakken H; Venizelos A; Perren A; Couvelard A; Lothe IMB; Hjortland GO; Myklebust TÅ; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Vestermark LW; Knappskog S; Sorbye H
    Br J Cancer; 2024 Sep; 131(4):676-684. PubMed ID: 38909137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.
    Elvebakken H; Hjortland GO; Garresori H; Andresen PA; Janssen EAM; Vintermyr OK; Lothe IMB; Sorbye H
    J Neuroendocrinol; 2023 Apr; 35(4):e13256. PubMed ID: 37017614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
    Rinke A; Gress TM
    Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas.
    Frizziero M; Spada F; Lamarca A; Kordatou Z; Barriuso J; Nuttall C; McNamara MG; Hubner RA; Mansoor W; Manoharan P; Fazio N; Valle JW
    Neuroendocrinology; 2019; 109(2):100-112. PubMed ID: 30703770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.
    Venizelos A; Elvebakken H; Perren A; Nikolaienko O; Deng W; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Krogh M; Sorbye H; Knappskog S
    Endocr Relat Cancer; 2021 Nov; 29(1):1-14. PubMed ID: 34647903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network.
    Hadoux J; Kanaan C; Durand A; Hescot S; Hautefeuille V; Cadiot G; Tauveron I; Laboureau S; Do Cao C; Walter T; Petorin C; Blanchet O; Jannin A; Gu C; Faron M; Leteurtre E; Rousselet MC; Zakeyh JJ; Marchal A; Chatelain D; Beaulaton C; Hervieu V; Ducreux M; Scoazec JY; Baudin E
    Eur J Cancer; 2021 Jul; 152():100-115. PubMed ID: 34090142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
    Heetfeld M; Chougnet CN; Olsen IH; Rinke A; Borbath I; Crespo G; Barriuso J; Pavel M; O'Toole D; Walter T;
    Endocr Relat Cancer; 2015 Aug; 22(4):657-64. PubMed ID: 26113608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
    Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
    Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ctDNA in Neuroendocrine Carcinoma of Gastroenteropancreatic Origin or of Unknown Primary: The CIRCAN-NEC Pilot Study.
    Gerard L; Garcia J; Gauthier A; Lopez J; Durand A; Hervieu V; Lemelin A; Chardon L; Landel V; Gibert B; Lombard-Bohas C; Payen L; Walter T
    Neuroendocrinology; 2021; 111(10):951-964. PubMed ID: 33099543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rb Loss and
    Hijioka S; Hosoda W; Matsuo K; Ueno M; Furukawa M; Yoshitomi H; Kobayashi N; Ikeda M; Ito T; Nakamori S; Ishii H; Kodama Y; Morizane C; Okusaka T; Yanagimoto H; Notohara K; Taguchi H; Kitano M; Yane K; Maguchi H; Tsuchiya Y; Komoto I; Tanaka H; Tsuji A; Hashigo S; Kawaguchi Y; Mine T; Kanno A; Murohisa G; Miyabe K; Takagi T; Matayoshi N; Yoshida T; Hara K; Imamura M; Furuse J; Yatabe Y; Mizuno N
    Clin Cancer Res; 2017 Aug; 23(16):4625-4632. PubMed ID: 28455360
    [No Abstract]   [Full Text] [Related]  

  • 12. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
    Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
    Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.
    Yamaguchi T; Machida N; Morizane C; Kasuga A; Takahashi H; Sudo K; Nishina T; Tobimatsu K; Ishido K; Furuse J; Boku N; Okusaka T
    Cancer Sci; 2014 Sep; 105(9):1176-81. PubMed ID: 24975505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3).
    Ali AS; Grönberg M; Langer SW; Ladekarl M; Hjortland GO; Vestermark LW; Österlund P; Welin S; Grønbæk H; Knigge U; Sorbye H; Janson ET
    Med Oncol; 2018 Mar; 35(4):47. PubMed ID: 29511910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913).
    Riesco-Martinez MC; Capdevila J; Alonso V; Jimenez-Fonseca P; Teule A; Grande E; Sevilla I; Benavent M; Alonso-Gordoa T; Custodio A; Anton-Pascual B; Hernando J; Polo E; Castillo-Trujillo OA; Lamas-Paz A; Teijo A; Rodriguez-Gil Y; Soldevilla B; Garcia-Carbonero R
    Nat Commun; 2024 Aug; 15(1):6753. PubMed ID: 39117670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC).
    Lamarca A; Frizziero M; Barriuso J; McNamara MG; Hubner RA; Valle JW
    Clin Transl Oncol; 2019 Jul; 21(7):950-953. PubMed ID: 30506132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma.
    McGarrah PW; Leventakos K; Hobday TJ; Molina JR; Finnes HD; Westin GF; Halfdanarson TR
    Pancreas; 2020 Apr; 49(4):529-533. PubMed ID: 32282766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of clinicopathological characteristics, therapeutic strategy and prognosis of 501 patients with gastric neuroendocrine neoplasms attending a single center].
    Zhang BL; Lu YX; Liang WQ; Gao YH; Xi HQ; Wang XX; Zhang KC; Chen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):459-466. PubMed ID: 37217354
    [No Abstract]   [Full Text] [Related]  

  • 19. Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study.
    Hadoux J; Walter T; Kanaan C; Hescot S; Hautefeuille V; Perrier M; Tauveron I; Laboureau S; Do Cao C; Petorin C; Blanchet O; Faron M; Leteurtre E; Rousselet MC; Joubert Zakeyh J; Marchal A; Chatelain D; Beaulaton C; Hervieu V; Lombard-Bohas C; Ducreux M; Scoazec JY; Baudin E; ;
    Endocr Relat Cancer; 2022 Oct; 29(10):569-580. PubMed ID: 35920609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series.
    Imai H; Shirota H; Okita A; Komine K; Saijo K; Takahashi M; Takahashi S; Takahashi M; Shimodaira H; Ishioka C
    Chemotherapy; 2016; 61(3):111-6. PubMed ID: 26636658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.